Investment Focus

First-in-class science, narrow by design.

Taiho Ventures concentrates where its team's oncology drug-development experience runs deepest — defined by a tight set of criteria.

Sectors

We invest across three sources of innovation.

Drug discovery

First-in-class or new-biology approaches.

Platform technologies

New platforms for drug discovery.

III

Spin-outs

Opportunities emerging from Taiho's pipelines.

Modality

We invest across modalities — from small molecules to biologics and oncolytic virus.

And we consider gene and cell therapy opportunistically.

Small moleculesBiologicsOncolytic virusGene & cell therapy

Stage

We invest early: from research through Pre-IND, and selectively from IND to proof-of-concept.

Core mandateSelective

Research

Pre-IND

IND

Proof-of-concept

Inside the criteria

These criteria come from the bench.

Our investment team includes scientists who advanced oncology programs at Taiho Pharmaceutical — through discovery, IND, and into the clinic. Taiho Ventures was founded in 2016 by Sakae Asanuma, CFA.

See the team